Abbvie Inc. signed a $1.1 billion New Year’s Eve deal with China’s Zelgen Biopharmaceuticals Co. Ltd., gaining ex-China ...

Four optimization trends dominated the med-tech industry in 2025. Growth-driven acquisitions propelled major players into hot ...

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate ...

Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the ...

In a recent publication in Molecular Therapy, researchers from Drexel University College of Medicine and UMass Chan Medical ...

The U.S. FDA dashed hopes that Corcept Therapeutics Inc. might be able to launch its selective glucocorticoid receptor ...

A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, ...

The U.S. FDA recently cleared Medtronic plc’s Hugo robotic-assisted surgery system and CMR Surgical Ltd.’s Versius Plus ...

Guangzhou Runer Ophthalmic Biotechnology Co. Ltd. has identified complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, asthma, ...

On the last day of the year, shares of Axsome Therapeutics Inc. rose 22% on news that the U.S. FDA accepted and granted priority review of the company’s supplemental NDA for AXS-05 to treat ...

If the 2025 U.S. life sciences regulatory scene were to be summed up in one word, it would have to be uncertainty. Two words might be more definitive – chaotic uncertainty.

Wife-and-husband team, J. Jean Cui and Y. Peter Li, launched Blossomhill Therapeutics Inc. in mid-2020 to focus on next-generation, macrocyclic inhibitors against oncology targets. The couple had ...